Abstract
Background Impaired brain glucose metabolism is a preclinical feature of neurodegenerative diseases such as Alzheimer’s disease (AD). Infections may promote AD-related pathology. Therefore, we investigated the interplay between infections and APOE4, a strong genetic risk factor for AD.
Methods We analyzed data on 1,509 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database using multivariate linear regression models. The outcomes were rank- normalized hypometabolic convergence index (HCI), statistical regions of interest (SROI) for AD, and mild cognitive impairment (MCI). Marginal mean estimates for infections, stratified by APOE4 carrier status, were then computed.
Results Prior infections were associated with greater HCI [β=0.15, 95% CI: 0.03, 0.27, p=0.01]. The combined effects of infections and APOE4 carriers on HCI levels were significantly greater than either variable alone. Among APOE4 carriers, the estimated marginal mean was 0.62, rising to 0.77, with infections (p<0.001), indicating an interaction effect. Carriers with multiple infections showed greater hypometabolism (higher HCI), with an estimate of 0.44 (p=0.01) compared to 0.11 (p=0.08) for those with a single infection, revealing a dose-response relationship. The estimates for the association of infections with SROI AD and SROI MCI were β=-0.01 (p=0.02) and β=-0.01 (p=0.04), respectively.
Conclusion Our findings suggest that infections and APOE4 jointly contribute to brain glucose hypometabolism and AD pathology, supporting a “multi-hit” mechanism in AD development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the National Institutes of Health's National Institute on Aging (NIA/NIH) grants R01AG076019 and R01AG062623. This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA/NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Duke University Health System issued approval for this study (Protocol IDs Pro00109279 and Pro00105389). This publication includes only secondary analyses of existing data available from ADNI, and does not include identifiable human data. Written informed consent for ADNI participants was obtained by the ADNI in accordance with the local legislation and ADNI requirements. ADNI studies follow Good Clinical Practices guidelines, the Declaration of Helsinki, and United States regulations (U.S. 21 CFR Part 50 and Part 56).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We have revised the abstract, updated the author details, and corrected the funding information.
Data Availability
The data used in this manuscript were obtained from the publicly available ADNI database (adni.loni.usc.edu). The ADNI database contains anonymized patient information, making it a secure data repository.
Abbreviations
- AD
- Alzheimer’s disease
- AIC
- Akaike Information Criterion
- APOE
- Apolipoprotein E
- Aβ
- Amyloid βeta
- FDG
- 18F-fluorodeoxyglucose
- GxE
- Gene-environment interaction
- GWAS
- Genome-wide association studies
- HSV
- Herpes Simplex Virus
- %INCMSE
- Percent Increase in Mean Squared error
- IQR
- Interquartile Range
- PET
- Positron Emission Tomography
- pTau
- Phosphorylated Tau
- SD
- Standard Deviation
- SNP
- Single Nucleotide Polymorphism
- SROI
- Statistical Region of Interest
- NECTIN2
- Nectin Cell Adhesion Molecule 2 (gene)
- PUD
- Peptic Ulcer Disease
- UTI
- Urinary Tract Infection